Nectar Lifesciences Limited Share Price & Company Info
- Market cap
- ₹198 Cras reported by NSE
- 52-week high
- ₹22.4023-DEC-2025
- 52-week low
- ₹9.3030-MAR-2026
- Face value
- ₹1.00
- Shares issued
- 19,42,60,970
- Volume
- 1,37,544₹0.14 Cr traded
- Delivery
- 76.68%of traded quantity
- Price band
- 5%₹9.82 – ₹10.84 on 2026-11-02
- Annual volatility
- 61.90%NSE, from daily returns
- Series
- EQrolling settlement
- BSE group
- Bscrip code 532649
- ISIN
- INE023H01027
- Listed on NSE
- 18-Jul-2005
About Nectar Lifesciences Limited
Nectar Lifesciences Limited is listed on the National Stock Exchange of India under the symbol NECLIFE in the EQ series. NSE classifies it under the basic industry Pharmaceuticals, part of the Healthcare sector. Its shares were listed on NSE on 18-Jul-2005. Each share has a face value of ₹1.00.
In the end-of-day data for 16 November 2026 the stock closed at ₹10.31, down 3.28% on the day. NSE puts the company's market capitalisation at about ₹198 crore, which puts it among the smallest listed companies in India. Over the past 52 weeks it has traded between ₹9.30 and ₹22.40, so the last price is 10.9% above the low and 54.0% below the high.
1,37,544 shares changed hands that day, and 76.68% of them were taken as delivery rather than squared off intraday. A high delivery share means most of the day's buyers chose to hold the shares; a low one usually means the volume was mostly short-term trading.
EQ is the normal equity series: shares settle on the usual T+1 cycle and intraday trading is allowed.
NSE currently lists a regulatory note for this stock: “LT ASM-1 | EPS based on prev. 4 trailing Qtrs. in the scrip is zero”. Notes like these come from the exchange's surveillance and disclosure checks and can mean higher margins, trade-for-trade settlement or limits on trading. Check the NSE quote page for the current position before trading.
NSE puts the stock's annualised volatility at 61.90%. That is very high: moves of several percent in a single day are routine.
Because the share trades below ₹20, it also appears in our list of penny stocks under ₹20, which explains the extra risks that come with low-priced shares.
Nectar Lifesciences Limited quarterly results
In the quarter ended June 2026 (un-audited), Nectar Lifesciences Limited reported total income of ₹6.29 crore and a net loss of ₹13.14 crore, or ₹-0.69 per share.
A year earlier, in the June 2025 quarter, income was ₹281 crore with a net loss of ₹63.23 crore. Income has fallen 97.8% year on year.
Nectar Lifesciences Limited was profitable in 1 of the 5 quarters shown below. Figures are as filed with NSE, in ₹ crore.
| Quarter ended | Total income | Profit before tax | Net profit | EPS | Status |
|---|---|---|---|---|---|
| June 2026 | 6.29 | -21.65 | -13.14 | -0.69 | Un-Audited |
| March 2026 | 7.58 | -56.92 | -67.92 | -1.85 | Audited |
| December 2025 | 0.66 | 56.60 | 14.27 | 3.02 | Un-Audited |
| September 2025 | 5.74 | -0.51 | -176 | -0.01 | Un-Audited |
| June 2025 | 281 | -96.75 | -63.23 | -2.82 | Un-Audited |
Nectar Lifesciences Limited shareholding pattern
At the end of September 2026, promoters and the promoter group held 51.84% of Nectar Lifesciences Limited, with the public holding 48.16%. That is up 7.31 percentage points from 44.53% in March 2025.
| Quarter ended | Promoter & Promoter Group (%) | Public (%) |
|---|---|---|
| September 2026 | 51.84 | 48.16 |
| June 2026 | 51.84 | 48.16 |
| March 2026 | 51.84 | 48.16 |
| January 2026 | 51.84 | 48.16 |
| December 2025 | 44.91 | 55.09 |
| September 2025 | 44.91 | 55.09 |
| June 2025 | 44.53 | 55.47 |
| March 2025 | 44.53 | 55.47 |
Nectar Lifesciences Limited share price performance
Over the past year the Nectar Lifesciences Limited share price has lost 34.60%, against a fall of 10.92% for the NIFTY 50, so it has underperformed that index by 23.68 percentage points.
Across the 7 periods in the table, the stock beat the NIFTY 50 in 1. Past returns describe what happened; they do not predict what comes next.
| Period | NECLIFE | NIFTY 50 |
|---|---|---|
| 1 month | -1.90% | +1.91% |
| 3 months | +1.18% | -5.20% |
| 6 months | -17.00% | -3.94% |
| 1 year | -34.60% | -10.92% |
| 2 years | -71.33% | -5.29% |
| 3 years | -55.31% | +20.44% |
| 5 years | -60.98% | +30.45% |
Nectar Lifesciences Limited vs industry peers
NSE compares Nectar Lifesciences Limited with 6 other listed companies in Pharmaceuticals. By market capitalisation it ranks 4 of 7.
| Company | Market cap | Price (₹) | P/E | Promoter % | Qtr income | Qtr net profit |
|---|---|---|---|---|---|---|
| AMBALALSA | 266 | 34.75 | — | 0.00 | — | — |
| ACCPL | 211 | 190.05 | 21.85 | 73.52 | — | — |
| SATKARTAR | 205 | 130.00 | 10.78 | 0.00 | — | — |
| NECLIFE | 200 | 10.30 | — | 51.84 | 6.29 | -13.14 |
| BMLL | 189 | 150.00 | — | 67.70 | — | — |
| BROOKS | 177 | 60.15 | 13.50 | 52.62 | 23.14 | 1.42 |
| MEDICO | 154 | 18.50 | 11.18 | 61.38 | 70.57 | 2.52 |
Nectar Lifesciences Limited announcements, board meetings and corporate actions
Latest announcements
The most recent filings Nectar Lifesciences Limited has made with NSE, newest first:
- 06-Oct-2026 · Certificate under SEBI (Depositories and Participants) Regulations, 2018: Nectar Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 (PDF)
- 05-Oct-2026 · Shareholders meeting: Nectar Lifesciences Limited has informed the Exchange with copy of minutes of Annual General Meeting held on September 18, 2026 (PDF)
- 03-Oct-2026 · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company: Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company (PDF)
- 24-Sep-2026 · Trading Window: Nectar Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 (PDF)
- 19-Sep-2026 · General Updates: Please find attached herewith Revised Proceedings of 31st Annual General Meeting (PDF)
- 18-Sep-2026 · Shareholders meeting: Nectar Lifesciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 18, 2026. Further, the company has informed the Exchange regarding voting results. (PDF)
- 18-Sep-2026 · Shareholders meeting: Nectar Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 18, 2026 (PDF)
- 22-Aug-2026 · General Updates: Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015. (PDF)
Board meetings
- 14-Aug-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
- 30-May-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended March 31, 2026 and other business matters
- 23-Jan-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended December 31, 2025 and other business matters
- 03-Dec-2025 · Buyback/Other business matters: To consider buyback for equity shares and other business matters
- 14-Nov-2025 · Financial Results/Other business matters: To consider and approve the financial results for the period ended September 30, 2025 and other business matters
Corporate actions
The corporate actions on record include 5 dividends. The ex-date is the first day the shares trade without the entitlement.
- Buy Back · ex-date 24-Dec-2025 · record date 24-Dec-2025
- Annual General Meeting · ex-date 13-Sep-2024 · book closure 15-Sep-2024 to 21-Sep-2024
- Annual General Meeting · ex-date 14-Sep-2023 · book closure 15-Sep-2023 to 21-Sep-2023
- Annual General Meeting · ex-date 13-Sep-2022 · book closure 15-Sep-2022 to 21-Sep-2022
- Annual General Meeting · ex-date 13-Sep-2021 · book closure 15-Sep-2021 to 21-Sep-2021
- Annual General Meeting/Dividend - Rs 0.05 Per Share · ex-date 11-Sep-2020 · book closure 15-Sep-2020 to 21-Sep-2020
- Annual General Meeting/Dividend - Rs 0.05 Per Share · ex-date 19-Sep-2019 · book closure 22-Sep-2019 to 28-Sep-2019
- Annual General Meeting/Dividend- Re 0.05 Per Share · ex-date 19-Sep-2018 · book closure 22-Sep-2018 to 28-Sep-2018
- Annual General Meeting/Dividend - Re 0.05 Per Share · ex-date 20-Sep-2017 · book closure 22-Sep-2017 to 28-Sep-2017
- Annual General Meeting/Dividend - Re 0.10 Per Share · ex-date 22-Sep-2016 · book closure 24-Sep-2016 to 30-Sep-2016
Risk notice: low-priced and small-company shares can be illiquid, volatile and subject to manipulation, and shareholders can lose their entire investment. This page is a factual summary, not a recommendation to buy or sell Nectar Lifesciences Limited.
Where to find Nectar Lifesciences Limited's financials
Direct downloads from NSE:
- Annual report 2025-26 (PDF, 5.18 MB)
- Annual report 2024-25 (PDF, 13.21 MB)
- Annual report 2023-24 (PDF)
- Annual report 2022-23 (ZIP)
- Annual report 2021-22 (ZIP)
- Annual report 2020-21 (ZIP)
For full financial statements, shareholding detail and every company announcement, go to the source:
- NSE quote pageOfficial price, price band, surveillance status, shareholding pattern and corporate actions.
- Annual reports (NSE)Search “NECLIFE” to download Nectar Lifesciences Limited's annual reports as filed with the exchange.
- Announcements and results (NSE)Search “NECLIFE” for quarterly results, board meetings and other company filings.
- BSE quote page (532649)BSE price, filings, results and shareholding for the same company.
- ScreenerTen years of profit and loss, balance sheet, cash flow and key ratios.
- TradingView chartInteractive price chart with technical indicators.
- Google FinanceQuick price overview and recent news coverage.
- Yahoo FinanceHistorical prices you can download, plus summary statistics.
Other Pharmaceuticals stocks on MCX Trends
- Syncom Formulations (India) Limited (SYNCOMF · ₹21.19)
- Anlon Healthcare Limited (AHCL · ₹25.77)
- Sigachi Industries Limited (SIGACHI · ₹28.16)
- Vineet Laboratories Limited (VINEETLAB · ₹37.52)
- Ambalal Sarabhai Enterprises Limited (AMBALALSA · ₹38.62)
- Medico Remedies Limited (MEDICO · ₹18.31)
- Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM · ₹30.67)
- Mangalam Drugs And Organics Limited (MANGALAM · ₹28.60)
Frequently asked questions
What is the Nectar Lifesciences Limited share price?
Nectar Lifesciences Limited (NSE: NECLIFE) closed at ₹10.31 in the end-of-day data for 16 November 2026. For a live price, use the NSE quote page or your broker, because this page is updated from end-of-day files.
Which sector does Nectar Lifesciences Limited belong to?
NSE classifies Nectar Lifesciences Limited under Pharmaceuticals, in the Healthcare sector.
What is the 52-week high and low of NECLIFE?
The 52-week high is ₹22.40 (23-DEC-2025) and the 52-week low is ₹9.30 (30-MAR-2026), according to NSE.
Is Nectar Lifesciences Limited a penny stock?
At ₹10.31 the share trades below ₹20, so it appears on our list of penny stocks under ₹20. A low share price on its own says nothing about whether a company is cheap or expensive; market capitalisation, debt, profits and exchange surveillance status matter far more.
What is the promoter holding in Nectar Lifesciences Limited?
Promoters and the promoter group held 51.84% of Nectar Lifesciences Limited at the end of September 2026, according to the shareholding pattern filed with NSE.
What were Nectar Lifesciences Limited's latest quarterly results?
For the quarter ended June 2026, Nectar Lifesciences Limited reported total income of ₹6.29 crore and a net loss of ₹13.14 crore (EPS ₹-0.69).
Where can I find Nectar Lifesciences Limited's annual report and financial results?
Annual reports, quarterly results and other filings are published on the NSE corporate filings pages (search for NECLIFE) and on BSE. Screener also lays out several years of financial statements in one place. Links to all of these are above.